Ikena Oncology
Patient-directed oncology therapies across pathways relevant in tumor and immune cells.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $75.0m | Private Placement VC | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (33 %) | 237 % | (50 %) | (41 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (133 %) | (481 %) | (108 %) | (449 %) | (890 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (122 %) | (481 %) | (110 %) | (440 %) | (744 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 181 % | 488 % | 152 % | 412 % | 651 % | - |
Source: Company filings or news article
Related Content
Ikena Oncology is a biotechnology company focused on developing targeted therapies for cancer patients. The company operates in the oncology market, aiming to address the unmet needs of patients by targeting specific nodes of cancer growth, spread, and therapeutic resistance. Ikena's business model revolves around the research and development of differentiated oncology therapies, leveraging a deep institutional knowledge and a broad array of tools to create the right drug for the right patient. The company generates revenue through partnerships, licensing agreements, and the eventual commercialization of its therapies. Ikena serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, all focused on improving cancer treatment outcomes.
Keywords: targeted oncology, cancer therapies, drug development, biotechnology, cancer growth, therapeutic resistance, healthcare providers, research institutions, pharmaceutical partnerships, commercialization.
Tech stack
Investments by Ikena Oncology
Edit